The Latest Breaking News from MRNA

Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, just days before it reconvenes to vote on COVID-19 shots and other routine pediatric vaccine recommendations.

Editor’s Note: This article has been updated to reflect the correct year-to-date performance of Moderna stock.

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze